Is gene editing a good investment?

Investing in gene editing is a high-risk, but potentially high-reward, proposition. This could be a good investment for patient, long-term investors who are willing to take on greater risk.

Which company is the leader in gene editing?

CRISPR Therapeutics is the only gene-editing company with an approved product on the market.

What stock is the king of genetic sequencing?

Illumina (NASDAQ:ILMN) most deserves the distinction of being called "the king of genetic sequencing." The company claims the top market share, by far, in genetic sequencing.

Do gene-editing companies typically pay dividends?

No, gene-editing companies typically don't pay dividends.

How do clinical trials affect gene-editing stock prices?

The results from clinical trials can significantly affect gene-editing stock prices. Positive results can cause a stock to soar, while negative results can cause shares to sink. However, sometimes clinical trial results don't cause gene-editing stocks to move much when the expected outcomes of the studies are already largely baked into the share price.

Should investors diversify when investing in gene-editing stocks?

Absolutely. Diversification helps reduce investing risk when investing in any type of stock. However, it's especially important when investing in gene-editing stocks because of the possibility of failure in clinical trials and in winning regulatory approvals.

Where can I find information and regular updates about the gene editing industry?

One source for staying informed about the gene-editing industry is to follow leaders such as Jennifer Doudna and Feng Zhang on X (formerly Twitter) and other social media platforms. You can also read articles available on websites such as CRISPR Medicine News, Genetic Engineering & Biotechnology News, The American Society of Gene & Cell Therapy, and the Genetic Literacy Project Regulation Tracker.

Is CRISPR a good stock to invest in?

CRISPR Therapeutics could be worthy of consideration for investors who aren't afraid to take on significant risk. Even though the company has an approved product, a major pipeline setback could cause the stock to sink.

Best Gene-Editing Stocks for 2026 and How to Invest

Best Gene Editing Stocks for 2026 and How to Invest

Key Points

The gene-editing market is projected to grow to $30.8 billion by 2032, highlighting investment potential.
CRISPR Therapeutics, co-founder by Charpentier, gains momentum with FDA-approved therapies.
Intellia Therapeutics, co-founded by Doudna, is advancing in vivo CRISPR treatments in clinical trials.

Loading paragraph...

Ticker Information Table
Name and ticker	Market cap	Dividend yield	Industry
Intellia Therapeutics (NASDAQ:NTLA)	$1.7 billion	0.00%	Biotechnology
CRISPR Therapeutics (NASDAQ:CRSP)	$5.5 billion	0.00%	Biotechnology
Beam Therapeutics (NASDAQ:BEAM)	$3.1 billion	0.00%	Biotechnology
Caribou Biosciences (NASDAQ:CRBU)	$204.9 million	0.00%	Biotechnology
Sangamo Therapeutics (NASDAQ:SGMO)	$106.0 million	0.00%	Biotechnology

Data as of Apr 15, 2026. Showing 5 of 5 tickers.

Loading ticker_table...

Loading paragraph...

NASDAQ: NTLA

Intellia Therapeutics

Today's Change

(0.54%) $0.08

Current Price

$14.86

Key Data Points

Market Cap

$1.7B

Day's Range

$14.83 - $15.26

52wk Range

$6.73 - $28.25

Volume

15K

Avg Vol

4.4M

Gross Margin

76.43%

Loading company_card...

Intellia (NTLA +1.76%) was co-founded by Jennifer Doudna in 2014. Its mission is to "develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases."

In 2021, Intellia and its partner, Regeneron Pharmaceuticals (REGN -1.33%), announced the first clinical data supporting the use of in vivo (in the body) CRISPR-Cas9 gene editing in humans. The two companies are now working together to evaluate nexiguran ziclumeran (formerly known as NTLA-2001) in a late-stage study targeting the rare genetic disease transthyretin amyloidosis (ATTR).

Intellia also has a wholly owned late-stage candidate, lonvoguran ziclumeran (Lonvo-z). It hopes to file for U.S. regulatory approval of the experimental therapy to treat hereditary angioedema (HAE) in the second half of 2026 and launch it commercially in the U.S. in 2027.

In addition, Regeneron is evaluating a hemophilia B therapy licensed from Intellia in phase 2 clinical testing. Intellia will be eligible for milestone payments and royalties if the experimental therapy advances through clinical development and ultimately wins regulatory approval.

2. CRISPR Therapeutics

Loading paragraph...

NASDAQ: CRSP

CRISPR Therapeutics

Today's Change

(0.98%) $0.56

Current Price

$57.42

Key Data Points

Market Cap

$5.5B

Day's Range

$57.20 - $59.38

52wk Range

$33.03 - $78.48

Volume

26K

Avg Vol

1.9M

Gross Margin

-653467.24%

Loading company_card...

CRISPR Therapeutics (CRSP +2.00%) was co-founded by Emmanuelle Charpentier in 2013. The company's mission is "developing transformative gene-based medicines for serious human diseases."

CRISPR Therapeutics and its big partner, Vertex Pharmaceuticals (VRTX -1.20%), became the first to win regulatory approval for a CRISPR gene-editing therapy in December 2023, with Casgevy for treating sickle cell disease. The two companies won U.S. Food and Drug Administration (FDA) approval the following month for Casgevy to treat transfusion-dependent beta-thalassemia.

The commercial launch of Casgevy continues to gain momentum, with Vertex leading the charge. Meanwhile, CRISPR Therapeutics is advancing several other gene-editing programs.

The company's pipeline includes an allogeneic chimeric antigen receptor T cell (CAR-T) therapy in clinical testing -- CTX112. Allogeneic (meaning involving genetically distinct tissues or cells) CAR-T therapies are often referred to as "off-the-shelf" because they don't require a patient's own cells to be genetically edited; instead, they use cells from healthy donors.

CRISPR Therapeutics is evaluating several in vivo gene-editing therapies, two of which are in clinical studies. The company is also conducting clinical testing of an experimental therapy for treating Type 1 diabetes.

3. Beam Therapeutics

Loading paragraph...

NASDAQ: BEAM

Beam Therapeutics

Today's Change

(0.53%) $0.16

Current Price

$30.46

Key Data Points

Market Cap

$3.1B

Day's Range

$30.32 - $31.36

52wk Range

$15.35 - $36.44

Volume

274K

Avg Vol

1.9M

Gross Margin

84.05%

Loading company_card...

Loading paragraph...

NASDAQ: CRBU

Caribou Biosciences

Today's Change

(3.30%) $0.07

Current Price

$2.19

Key Data Points

Market Cap

$205M

Day's Range

$2.13 - $2.19

52wk Range

$0.71 - $3.54

Volume

29K

Avg Vol

1.3M

Gross Margin

67.34%

Loading company_card...

Intellia Therapeutics isn't the only gene-editing company co-founded by Jennifer Doudna. The Nobel Prize winner also co-founded Caribou Biosciences (CRBU +3.30%) in 2011, along with CRISPR gene-editing pioneers James Berger and Martin Jinek, and Caribou's CEO, Rachel Haurwitz.

Caribou has developed Cas12a chRDNA ("CRISPR hybrid RNA-DNA," pronounced "chardonnay") technology, a next-generation version of CRISPR gene editing. The company's approach uses hybrid RNA and DNA guides for editing DNA, rather than relying solely on RNA guides. This technology reduces the chances of off-target edits.

The gene-editing company's pipeline features two experimental allogeneic (off-the-shelf) cancer cell therapies in early-stage clinical trials. Vispa-cel (formerly CB-010) targets relapsed or refractory B-cell non-Hodgkin's lymphoma. CB-011 targets relapsed or refractory multiple myeloma.

5. Sangamo Therapeutics

Loading paragraph...

NASDAQ: SGMO

Sangamo Therapeutics

Today's Change

(-1.09%) $-0.00

Current Price

$0.25

Key Data Points

Market Cap

$106M

Day's Range

$0.25 - $0.26

52wk Range

$0.20 - $0.84

Volume

1.3M

Avg Vol

6.9M

Gross Margin

80.78%

Loading company_card...

Loading paragraph...

Loading pitch...

Loading paragraph...

Loading pitch...

Investing in gene-editing stocks FAQ

Loading faq...

About the Author

Keith Speights is a contributing Motley Fool healthcare analyst covering publicly traded companies across pharmaceuticals, biotechnology, medical devices, technology, and marijuana. Prior to The Motley Fool, Keith was CEO of Constant Care Technology, a healthcare technology company; vice president of American HealthTech, a healthcare software company; and a director of operations for Blue Cross Blue Shield of Mississippi, a health insurer. He holds a B.S. in Industrial Engineering from Mississippi State University.

TMFFishBiz

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Beam Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Best Gene Editing Stocks for 2026 and How to Invest

Key Points

Key Data Points

2. CRISPR Therapeutics

Key Data Points

3. Beam Therapeutics

Key Data Points

Key Data Points

5. Sangamo Therapeutics

Key Data Points

Related investing topics

Best Healthcare Stocks to Buy in 2026 and How to Invest in Them

Best Health Insurance Stocks for 2026 and How to Invest

Best Biotech Stocks to Buy in 2026 and How to Invest in Them

Best Pharmaceutical Stocks to Buy in 2026 and How to Invest in Them

Investing in gene-editing stocks FAQ

Is gene editing a good investment?

Is gene editing a good investment?

Which company is the leader in gene editing?

Which company is the leader in gene editing?

What stock is the king of genetic sequencing?

What stock is the king of genetic sequencing?

Do gene-editing companies typically pay dividends?

Do gene-editing companies typically pay dividends?

How do clinical trials affect gene-editing stock prices?

How do clinical trials affect gene-editing stock prices?

Should investors diversify when investing in gene-editing stocks?

Should investors diversify when investing in gene-editing stocks?

Where can I find information and regular updates about the gene editing industry?

Where can I find information and regular updates about the gene editing industry?

Is CRISPR a good stock to invest in?

Is CRISPR a good stock to invest in?

About the Author

Read Next

Stocks Mentioned

Premium Investing Services

Investing in gene-editing stocks FAQ

Is gene editing a good investment?

Is gene editing a good investment?

Which company is the leader in gene editing?

Which company is the leader in gene editing?

What stock is the king of genetic sequencing?

What stock is the king of genetic sequencing?

Do gene-editing companies typically pay dividends?

Do gene-editing companies typically pay dividends?

How do clinical trials affect gene-editing stock prices?

How do clinical trials affect gene-editing stock prices?

Should investors diversify when investing in gene-editing stocks?

Should investors diversify when investing in gene-editing stocks?

Where can I find information and regular updates about the gene editing industry?

Where can I find information and regular updates about the gene editing industry?

Is CRISPR a good stock to invest in?

Is CRISPR a good stock to invest in?

Top gene-editing stocks for 2026

Best Healthcare Stocks to Buy in 2026 and How to Invest in Them

Best Health Insurance Stocks for 2026 and How to Invest

Best Biotech Stocks to Buy in 2026 and How to Invest in Them

Best Pharmaceutical Stocks to Buy in 2026 and How to Invest in Them

1. Intellia Therapeutics

Benefits and risks of investing in gene-editing stocks

Should you invest in gene-editing stocks?

Related investing topics

FAQ

Key Data Points

Key Data Points

Key Data Points

Key Data Points

2. CRISPR Therapeutics

3. Beam Therapeutics

4. Caribou Biosciences

5. Sangamo Therapeutics

How to buy gene-editing stocks

Key Data Points